Who Pays My Doctor?

Healthcare provider profile · identity verified

John Joseph Ryan, MBBCHBAO

Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · SALT LAKE CITY, UT · NPI 1902071673

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show John Joseph Ryan, MBBCHBAO received $320,001.05 in general payments during 2025 across 322 reported records.

Actelion Pharmaceuticals US, Inc. accounted for 41.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 14 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Opsumit.

Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Opsumit by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$320,001.05

322 reported records · 10 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Actelion Pharmaceuticals US, Inc. Unresolved — no canonical attribution shown $131,253.5141.0%1392025
United Therapeutics Corporation Unresolved — no canonical attribution shown $84,568.4926.4%842025
Merck Sharp & Dohme LLC Unresolved — no canonical attribution shown $60,727.2319.0%492025
SCPHARMACEUTICALS INC. Unresolved — no canonical attribution shown $31,974.0210.0%242025
Bayer Healthcare Pharmaceuticals Inc. Unresolved — no canonical attribution shown $11,170.533.5%192025
Insmed, Inc. Unresolved — no canonical attribution shown $122.910.0%32025
Chiesi USA, Inc. Unresolved — no canonical attribution shown $109.860.0%12025
Novo Nordisk Inc Unresolved — no canonical attribution shown $34.860.0%12025
Sandoz Inc. Unresolved — no canonical attribution shown $19.940.0%12025
Liquidia Technologies, Inc. Unresolved — no canonical attribution shown $19.700.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$212,343.0047
Travel and Lodging$50,371.77160
Honoraria$28,525.006
Consulting Fee$22,160.003
Food and Beverage$6,601.28106

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
UPTRAVI
Normalized: uptravi		 Drug Actelion Pharmaceuticals US, Inc. $131,203.92 137 2025
Source payment records
OPSUMIT
Normalized: opsumit		 Drug Actelion Pharmaceuticals US, Inc. $130,895.67 130 2025
Source payment records
WINREVAIR
Normalized: winrevair		 Biological Merck Sharp & Dohme LLC $54,625.15 43 2025
Source payment records
REMODULIN
Normalized: remodulin		 Drug United Therapeutics Corporation $40,051.15 38 2025
Source payment records
FUROSCIX
Normalized: furoscix		 Drug SCPHARMACEUTICALS INC. $31,974.02 24 2025
Source payment records
TYVASO
Normalized: tyvaso		 Drug United Therapeutics Corporation $13,147.48 14 2025
Source payment records
Kerendia
Normalized: kerendia		 Drug Bayer Healthcare Pharmaceuticals Inc. $11,170.53 19 2025
Source payment records
ORENITRAM
Normalized: orenitram		 Drug United Therapeutics Corporation $10,523.06 3 2025
Source payment records
Adempas
Normalized: adempas		 Drug Bayer Healthcare Pharmaceuticals Inc. $8,783.50 4 2025
Source payment records
Arikayce
Normalized: arikayce		 Drug Insmed, Inc. $122.91 3 2025
Source payment records
Wegovy
Normalized: wegovy		 Drug Novo Nordisk Inc $34.86 1 2025
Source payment records
TREPROSTINIL
Normalized: treprostinil		 Drug Sandoz Inc. $19.94 1 2025
Source payment records
YUTREPIA
Normalized: yutrepia		 Drug Liquidia Technologies, Inc. $19.70 1 2025
Source payment records
OPSYNVI
Normalized: opsynvi		 Drug Actelion Pharmaceuticals US, Inc. $16.34 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
OPSUMIT
opsumit		 2025 Opsumit 2024 32
Beneficiary count suppressed		 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
Actelion Pharmaceuticals US, Inc.
Exact reporting entity; no affiliate inference		 2025 OPSUMIT
open payments reported associated product		 CMS Open Payments — General Payments
18955 supporting records · 8899 recipient NPIs · example record 1174163978 		Opsumit · 2024
Exact normalized brand match · 1 Part D row		 32 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
SpironolactoneSpironolactone11763
EntrestoSacubitril/Valsartan9734
Atorvastatin CalciumAtorvastatin Calcium8237
TorsemideTorsemide7630
FarxigaDapagliflozin Propanediol7322
FurosemideFurosemide6433
Losartan PotassiumLosartan Potassium5219
Metoprolol SuccinateMetoprolol Succinate4731
JardianceEmpagliflozin4518
CarvedilolCarvedilol4315
Potassium ChloridePotassium Chloride4115
OpsumitMacitentan32suppressed
Repatha SureclickEvolocumab30suppressed
EliquisApixaban2711
LisinoprilLisinopril2514
BumetanideBumetanide2211
Sildenafil CitrateSildenafil Citrate22suppressed
Rosuvastatin CalciumRosuvastatin Calcium2111
Olmesartan MedoxomilOlmesartan Medoxomil2012
ClopidogrelClopidogrel Bisulfate17suppressed
EzetimibeEzetimibe17suppressed
Amlodipine BesylateAmlodipine Besylate16suppressed
NitroglycerinNitroglycerin1612
Klor-Con M20Potassium Chloride14suppressed
Metoprolol TartrateMetoprolol Tartrate14suppressed
Albuterol Sulfate HfaAlbuterol Sulfate12suppressed
Isosorbide Mononitrate ErIsosorbide Mononitrate12suppressed
ArcalystRilonacept11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $320,001.05 · 322 records Actelion Pharmaceuticals US, Inc. Adempas, Arikayce, FUROSCIX, Kerendia, OPSUMIT, OPSYNVI, ORENITRAM, REMODULIN, TREPROSTINIL, TYVASO, UPTRAVI, WINREVAIR, Wegovy, YUTREPIA 1 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error